ReviewLife medicine2022
Genetic enhancement: an avenue to combat aging-related diseases.
Review in Life medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Review
- Genetically engineered senescence-resistant human mesenchymal progenitor cells promote spinal cord injury repair.Life medicine · 2026Article
- Interconnected Pathways and Therapeutic Implications for Cardiovascular Aging and Diseases.JACC. Asia · 2026Review
- Mitochondrial sirtuins, key regulators of aging.Life medicine · 2025Review
- Gene therapy strategies for aging intervention.Cell insight · 2025Review
- FOXO3-engineered human mesenchymal stem cells efficiently enhance post-ischemic stroke functional rehabilitation.Protein & cell · 2025Article
- CRISPR-based screening pinpoints H2AZ1 as a driver of senescence in human mesenchymal stem cells.Protein & cell · 2025Article
- CRISPR screening uncovers nucleolar RPL22 as a heterochromatin destabilizer and senescence driver.Nucleic acids research · 2024Article
- Ethical concerns in aging research: perspectives of global frontline researchers.Science China. Life sciences · 2024Article
- Human ESC-derived vascular cells promote vascular regeneration in a HIF-1α dependent manner.Protein & cell · 2024Article
- Migrasomes trigger innate immune activation and mediate transmission of senescence signals across human cells.Life medicine · 2023Article
- APOE-mediated suppression of the lncRNA MEG3 protects human cardiovascular cells from chronic inflammation.Protein & cell · 2023Article
- Deciphering RNA mAging cell · 2023Review
- CRISPR-based screening identifies XPO7 as a positive regulator of senescence.Protein & cell · 2023Article
- Biomarkers of aging.Science China. Life sciences · 2023Review
- A single-cell transcriptomic atlas of exercise-induced anti-inflammatory and geroprotective effects across the body.Innovation (Cambridge (Mass.)) · 2023Article
- MAVS Antagonizes Human Stem Cell Senescence as a Mitochondrial Stabilizer.Research (Washington, D.C.) · 2023Article
- An experimental workflow for identifying RNA mJournal of biological methods · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is a major risk factor for multiple diseases, including cardiovascular diseases, neurodegenerative disorders, osteoarthritis, and cancer. It is accompanied by the dysregulation of stem cells and other differentiated cells, and the impairment of their microenvironment. Cell therapies to replenish the abovementioned cells provide a promising approach to restore tissue homeostasis and alleviate aging and aging-related chronic diseases. Importantly, by leveraging gene editing technologies, genetic enhancement, an enhanced strategy for cell therapy, can be developed to improve the safety and efficacy of transplanted therapeutic cells. In this review, we provide an overview and discussion of the current progress in the genetic enhancement field, including genetic modifications of mesenchymal stem cells, neural stem cells, hematopoietic stem cells, vascular cells, and T cells to target aging and aging-associated diseases. We also outline questions regarding safety and current limitations that need to be addressed for the continued development of genetic enhancement strategies for cell therapy to enable its further applications in clinical trials to combat aging-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.